肠易激综合征
医学
膨胀
腹痛
小肠细菌生长过度
中医药
病因学
胃肠病学
内科学
病态的
功能性胃肠病
排便
吸收不良
功能紊乱
传统医学
替代医学
病理
作者
Zijuan Bi,Zheng Yu,Jianye Yuan,Zhaoxiang Bian
标识
DOI:10.2174/1381612823666170822101606
摘要
Irritable bowel syndrome (IBS) is one of the most common functional bowel disorders (FBD), which is characterized by recurrent abdominal pain, abdominal bloating/distention associated with defecation or changed bowel habits. Currently, there is no evidence of obvious anatomic or physiologic abnormalities on the routine diagnostic examinations. There are multiple pathological factors involved in IBS responsible for its heterogeneous nature, although the exact etiology and pathology of IBS are not well known and it is disappointed to develop biomarkers for this disorder. These factors including low-grade inflammation, activation of immune system, changed intestinal microorganism, small intestinal bacterial overgrowth (SIBO), malabsorption of bile acid (BA), increased number of mast cells (MCs). Current pharmacologic treatment for IBS focuses on alleviation of its symptoms, but not on the elimination of its cause. Although there are a lot of conventional chemical medicines for IBS available, due to the limited clinical benefits, high medical expenses and severe side effects, many IBS patients have turned to alternative medicine, particularly Chinese herbal medicine (CHM). Chinese herbal therapies have been used for thousand years in eastern Asia and have been provided that they are effective in relieving symptoms among IBS patients. Generally, traditional Chinese herbal formulae (CHF) consisting of CHM can be easily adjusted in accordance with concrete conditions, which means the treatment is based on syndrome differentiation and varied from individual to individual. Meanwhile, CHF/CHM containing many different ingredients may act on multiple sites/pathways with potential synergistic effects and chemical reactions. Keywords: Irritable bowel syndrome, Chinese herbal medicine, efficacy, mechanism, mast cells, small intestinal bacterial overgrowth.
科研通智能强力驱动
Strongly Powered by AbleSci AI